

The MicroRNA Expression Profile Differs Between Erythrodermic Mycosis Fungoides and Sézary Syndrome

Anne Hald RITTIG¹, Lise Maria LINDAHL¹, Claus JOHANSEN¹, Pamela CELIS², Niels ØDUM³, Lars IVERSEN¹ and Thomas I ITMAN³

¹Department of Dermatology, Aarhus University Hospital, ²Department of Molecular Medicine, Aarhus University, Aarhus, and ³Leo Foundation Skin Immunology Research Center; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark

Acta Dermato-Venereologica

ActaDV

It is difficult to distinguish erythrodermic mycosis fungoides from Sézary syndrome due to their similar clinical and histological features. The main purpose of this study was to investigate whether microRNA expression profiles in lesional skin could discriminate patients with erythrodermic mycosis fungoides from those with Sézarv syndrome. A further aim was to assess whether the microRNA expression profiles in erythrodermic mycosis fungoides skin was more comparable to microRNA expression profiles of Sézary syndrome or early-stage mycosis fungoides. RNA was extracted from diagnostic skin biopsies, followed by guantitative reverse transcription polymerase chain reaction analysis of 383 microRNAs. Twenty-seven microRNAs were significantly differentially expressed between erythrodermic mycosis fungoides and Sézary syndrome. Moreover, erythrodermic mycosis fungoides showed microRNA features overlapping with Sézary syndrome and early-stage mycosis fungoides, although hierarchical cluster analysis co-clustered erythrodermic mycosis fungoides with early-stage mycosis fungoides rather than with Sézary syndrome. These findings underscore that erythrodermic mycosis fungoides and Sézary syndrome are different diseases.

Key words: mycosis fungoides, Sézary syndrome, cutaneous Tcell lymphoma, microRNA.

Accepted Aug 26, 2019; E-published Aug 27, 2019

Acta Derm Venereol 2019; 99: 1148-1153.

Corr: Anne Hald Rittig, Department of Dermatology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, E201, DK-8200 Aarhus N, Denmark. E-mail: annehald@clin.au.dk

vutaneous T-cell lymphoma (CTCL) is a group of rare heterogeneous lymphoproliferative disorders primarily confined to the skin. The most prevalent clinical form of CTCL is mycosis fungoides (MF) (1, 2). Early-stage MF comprises patch and plaque skin lesions, whereas advanced stages involve skin tumours and erythrodermic MF (eMF) (3, 4). eMF and the more aggressive leukaemic variant, Sézary syndrome (SS), are characterized by chronic erythroderma with $\geq 80\%$ skin involvement (4). eMF and SS are difficult to distinguish because of their similar clinical features, with erythroderma and lymphadenopathy combined with symptoms such as pruritus, skin burning, and chills (5). However, eMF sometimes progresses through patch- and/or plaque-stage disease

SIGNIFICANCE

Erythrodermic mycosis fungoides and Sézary syndrome share clinical and histological features, making it difficult to distinguish these diseases. It has been discussed previously whether erythrodermic mycosis fungoides and Sézary syndrome are different stages of the same disease. However, differences in treatment and prognoses indicate that the diseases should be considered separately. MicroRNAs are small sequences of RNA, which have the potential to discriminate clinically similar diseases. This study showed that 27 microRNAs discriminated erythrodermic mycosis fungoides from Sézary syndrome. These data support the perception of erythrodermic mycosis fungoides and Sézary syndrome as different diseases.

and has various levels of blood involvement, whereas SS usually presents with erythroderma and significant blood involvement (6, 7). Controversies still exist regarding whether MF and SS are distinct diseases or different manifestations of a single disease (8, 9), which has led to substantial discussions about the distinction between eMF and SS (6, 9, 10). Discrimination between SS and eMF is essential due to differences in treatment recommendations and prognosis (7, 11, 12).

MicroRNAs (miRNAs) may have the potential to discriminate between SS and eMF. miRNAs are short non-coding RNA molecules that regulate gene expression by modulating translation of messenger RNA (13). Thus, miRNAs are involved in important biological functions, and altered regulation of miRNAs plays a key role in cancer development, progression and metastasis (14). Many miRNAs are differentially expressed in CTCL compared with normal skin (15–17). They have been proposed to discriminate CTCL from benign skin diseases as a diagnostic marker (18-20), and a prognostic 3-miRNA classifier was developed recently for patients diagnosed with early-stage MF (21). Moreover, single miRNAs (e.g. miR-155) may have essential regulatory functions in CTCL (22, 23), and a drug targeting miR-155, cobomarsen, was developed recently and tested in a clinical trial with promising outcomes (24).

This study examined the miRNA expression profiles of diagnostic lesional skin biopsies from early-stage MF, eMF, and SS, with the aim of: (i) examining whether a distinct miRNA expression profile can discriminate eMF from SS; and (ii) addressing whether the miRNA ActaDV

MicroRNAs in erythrodermic mycosis fungoides and Sézary syndrome

signature in eMF is more similar to the signature in SS than to the miRNA profile in early-stage MF skin.

METHODS

Patients

Formalin-fixed paraffin-embedded skin biopsies, used for firsttime diagnosis of early-stage MF, eMF and SS were collected. The study included 15 patients with early-stage MF, 14 with eMF and 11 with SS diagnosed in the period between 1981 and 2013. Patients with early-stage MF (stages IA-IB) were diagnosed and grouped in accordance with the International Society for Cutaneous Lymphomas/European Organization of Research and Treatment of Cancer (ISCL/EORTC) recommendations from 2007 (4). Early-stage patients have also been included in a previous study by Lindahl et al. (21). eMF and SS were categorized in accordance with the clinical guidelines at the time of diagnosis. A diagnosis of SS required erythroderma, compatible histology, and blood involvement of at least 5% of Sézary cells (25, 26). Relevant clinical variables, such as sex, age, and treatment at the time of diagnosis, were obtained from the patient files.

The study was approved by the local ethics committee (1-10-72-91-13) and the Danish Data Protection Agency (Datatilsynet 1-16-02-478-15).

RNA extraction and quantitative reverse transcription PCR (qRT-PCR) profiling

Biopsies were cut into 10-µm tissue sections, and RNA was extracted using the RecoverAll Total Nucleic Acid Isolation Kit (ThermoFisher Scientific/Applied Biosystems, Waltham, MA, USA) according to the manufacturer's guidelines. Total RNA quantity and quality controls were performed using a NanoDrop-1000 spectrophotometer. The extracted RNA was used for qRT-PCR-based miRNA profiling covering 383 human miRNAs, as described previously (21).

Statistical analysis

The miRNAs with signals close to or below the detection limit (Ct>37) in most or all samples were excluded from further analyses, leaving 264 specific miRNAs for further analyses. Data were normalized by a global mean approach.

Data were visualized by heatmaps and unsupervised hierarchical clustering in Olucore Omics Explorer v.3.4 (Olucore AB, Lund, Sweden). Analysis of variance (ANOVA) was used to detect differentially expressed miRNAs between the 3 groups. Differences in miRNA expression levels were considered significant at >1.5 fold-change (FC) and *p*-value < 0.05. Adjustment for multiple testing was carried out by estimation of the false discovery rate (Q value). Target prediction and pathway analysis were performed by applying DIANA-miRPath v.3.0 (27).

RESULTS

Patient characteristics

Patient characteristics are listed in Table I. A total of 40 patients were identified; 15 with early-stage MF, 14 with eMF and 11 with SS. Median age at diagnosis was 66 years (range 47–88 years) in patients with early-stage MF, 76 years (range 51–94 years) in patients with eMF, and 74 years (range 55-86 years) in patients with SS

and did not differ between the patient groups (1-way analysis of variance (ANOVA), p=0.12). Eleven patients with early-stage MF, 6 with eMF, and 3 with SS did not receive CTCL-directed therapy at the time of diagnosis. Topical treatment was assigned to 4 patients with earlystage MF, 8 with eMF, and 5 with SS. Systemic therapy was given to 3 patients with eMF, 3 with SS, and none of the early-stage MF patients at the time of diagnosis.

1149

miRNA expression profile can discriminate erythrodermic mycosis fungoides from Sézary syndrome

The miRNA expression profile was distinctly different in skin biopsies from patients with eMF compared with patients with SS (Fig. 1). Twenty-seven miRNAs with strong (FC>1.5) and significantly different expression in eMF vs. SS (Fig. 1) were identified. Fourteen miRNAs

Table I. Clinical characteristics

Pat. No.	Sex	Age at biopsy (years)	Treatment at time of diagnosis	Stage	T-stage
Mycosis fu	ngoides	T1 + T2			
1	F	70	No treatment	IB	2
2	Μ	66	No treatment		1
3	F	88	No treatment	IB	2
4	Μ	66	Ultraviolet B	IA	1
5	Μ	71	No treatment	IB	2
6	Μ	60	Topical steroid	IA	1
7	М	67	No treatment	IA	1
8	F	58	Topical steroid	IA	1
9	М	71	No treatment	IB	2
10	F	72	No treatment	IB	2
11	М	85	Ultraviolet B	IB	2
12	М	50	No treatment	IB	2
13	F	51	No treatment	IB	2
14	F	65	No treatment	IB	2
15	М	47	No treatment	IA	1
Mycosis fu	ngoides [·]	T4			
, 16	F	82	Oral steroid	IIIA	4
			Topical steroid		
17	М	79	Topical steroid	IIIA	4
18	М	51	Etretinate	IIIA	4
			Topical steroid		
19	F	83	Topical steroid	IIIA	4
20	М	68	No treatment	IIIA	4
21	М	74	Topical steroid	IIIA	4
22	М	84	Topical steroid	IIIA	4
23	М	76	Methotrexate	IIIA	4
			Topical steroid		
24	М	60	No treatment	IIIA	4
25	М	75	No treatment	IIIA	4
26	F	94	No treatment	IIIA	4
27	М	69	No treatment	IIIA	4
28	М	80	No treatment	IIIA	4
29	М	65	Topical steroid	IIIA	4
Sézary syr	ndrome				
30	М	55	Topical steroid		4
31	F	85	No treatment		4
32	M	75	No treatment		4
33	М	64	Topical steroid		4
34	M	65	Topical steroid		4
35	F	59	Topical steroid		4
36	F	83	No treatment		4
37	F	80	Topical steroid		4
38	M	80	Alemtuzumab		4
39	M	74	Oral steroid		4
40	M	64	Oral steroid		4
	••		Ciclosporin		•




Fig. 1. Heatmap of significantly differential expressed microRNAs between erythrodermic mycosis fungoides (eMF) and Sézary syndrome (SS). Heatmap and unsupervised 2-way hierarchical clustering based on the 27 microRNAs with strong (fold-change > 1.5) and significantly (p < 0.05) differential expression between eMF and SS.

were expressed at lower levels, and 13 were expressed at higher levels in eMF compared with in SS. Notably, miRNAs, such as miR-106b, miR-142, miR-155 and miR-21, which may play an important role in progression of CTCL (21, 22, 28, 29) had significantly lower expression levels in eMF compared with in SS. Unsupervised hierarchical clustering showed that the 27 differentially expressed miRNAs clearly separated eMF from SS (Fig. 1). Three patients with SS clustered with the eMF patients. Of note, 2 of these patients (patients 39 and 40) were treated with oral corticosteroids (daily dose 25 and 15 mg, respectively), whereas none of the other patients with SS received this treatment.

miRNA expression in erythrodermic mycosis fungoides (MF) and Sézary syndrome compared with early-stage MF

Next, miRNA expression in eMF and SS were compared with that in patients with early-stage MF. Twenty-eight

significantly differentially expressed miRNAs were identified in skin lesions from eMF compared with early-stage MF (p < 0.05, FC>1.5) (**Fig. 2**a). Two-way unsupervised hierarchical clustering based on the 28 differentially expressed miRNAs discriminated eMF from early-stage MF, albeit with some overlap. Patients 16, 20, 22, 25 and 26 diagnosed with eMF sub-clustered with 4 patients with early-stage MF before clustering with the rest of the patients with eMF. This subdivision of the eMF disease group did not depend on disease stage (IA/ IB) of the early-stage MF group, treatment at the time of diagnosis, or sex.

The miRNA expression in SS also differed from the expression pattern observed in early-stage MF. Thirty-four significantly differentially expressed miRNAs were identified (Fig. 2b, p < 0.05, >1.5 FC, Q < 0.30), which separated the 2 disease entities, as illustrated by the unsupervised hierarchical clustering (Fig. 2b). How-ever, the 2 patients with SS who were treated with oral corticosteroids (patients 39 and 40) clustered with the patients with early-stage MF. Thus, oral corticosteroid-induced skin improvement seems to induce changes in the miRNA expression pattern toward what is observed in early-stage MF.

Eleven miRNAs separated both eMF and SS from early-stage MF. Of these 11 miRNAs, 4 were expressed at significantly higher levels in SS and eMF vs. early-stage MF (miR-22-3p, miR-199a-3p, miR-199a-5p, miR-199b-5p), and 7 were expressed at significantly lower levels (miR-27b-5p, miR-328-3p, miR-342-3p, miR-433-3p, miR-483-3p, miR-484, and miR-663a).

Differentially expressed miRNAs between all patient groups

Fifty-four miRNAs were significantly differentially expressed between all patient groups (p < 0.05, Q=0.24). In the heatmap and unsupervised hierarchical clustering based on these 54 miRNAs, the 3 disease entities, eMF, SS and early-stage MF, separated into distinct clusters, although with some overlap (**Fig. 3**). Interestingly, eMF displays miRNA features overlapping with both those of SS and of early-stage MF, although the hierarchical cluster analysis suggests eMF co-clustering with early-stage MF rather than with SS.

Differences in predicted miRNA-induced downstream pathway activation

Differences in the miRNA expression profile between eMF and SS may reflect differences in downstream pathway activation between eMF and SS. Therefore, we performed a pathway analysis using DIANA-tools and miRPath v3.0 based on the 27 miRNAs that were significantly differentially expressed between eMF and SS. Pathways of particular interest in CTCL are shown in **Table II**, indicating possible involvement of signalling

$ \frac{1}{10000000000000000000000000000000000$	A			Dx		B		Dx hsa-miR-410-3p	
microRNA ID Log2 fold change P value Q value htsamiR-509-3p 3.15 0.008 0.121 htsamiR-1998-5p 1.80 0.005 0.099 htsamiR-23-23p 1.89 -0.001 0.028 htsamiR-132-5p 1.75 0.009 0.121 htsamiR-132-5p 1.75 0.010 0.120 htsamiR-132-5p 2.18 0.000 0.242 htsamiR-132-5p 1.87 0.005 0.099 htsamiR-1998-5p 1.47 -0.001 0.020 htsamiR-1998-3p 1.65 0.005 0.099 htsamiR-1998-3p 1.61 0.001 0.121 htsamiR-1998-3p 1.60 0.032 0.259 htsamiR-1998-3p 1.60 0.032 0.259 htsamiR-1938-3p 1.50 0.006 0.999 htsamiR-198-3p 1.60 0.032 0.255 htsamiR-198-3p 2.00 0.007 0.175 htsamiR-198-3p 1.00 0.001 0.121				ba-mit-204-5p ba-mit-242-2p ba-mit-1480-5p ba-mit-1480-5p ba-mit-282-3p ba-mit-282-3p ba-mit-282-3p ba-mit-282-3p ba-mit-282-3p ba-mit-282-3p ba-mit-282-3p ba-mit-272-5p	eMF 2.0 - 1.5 - 1.0 - 0.5 - 0.0 0.5 1.0 1.5			Ram 4335-59 Ram 4355-59 Ram 4435-59 Ram 4435-59 Ram 4435-59 Ram 4435-59 Ram 4435-59 Ram 4435-59 Ram 4435-59 Ram 4435-59 Ram 441-59 Ram 442-59 Ram 442-59 R	- 2.0 - 1.5 - 1.0 - 0.5 - 0.0 0.5 1.0 1.5
IssamiR-609.3p 0.02 0.02 0.121 IssamiR-262-3p 2.66 0.016 0.224 IssamiR-198e-5p 1.90 0.005 0.099 IssamiR-23-5p 2.23 0.003 0.156 IssamiR-1322-5p 1.89 -0.001 0.028 IssamiR-1432-5p 2.21 0.006 0.175 IssamiR-1333 1.75 0.009 0.121 IssamiR-14165-5p 2.17 0.030 0.266 IssamiR-335-5p 1.67 0.022 0.259 IssamiR-148a-5p 2.11 0.023 0.267 IssamiR-1398-3p 1.61 0.001 0.050 IssamiR-148a-3p 2.00 0.0002 0.121 IssamiR-1398-3p 1.61 0.006 0.099 IssamiR-148a-3p 2.00 0.0002 0.121 IssamiR-1308-3p 1.51 0.006 0.099 IssamiR-142-5p 1.00 0.002 0.121 IssamiR-1308-3p 1.60 0.033 0.2281 IssamiR-142-5p 1.00 0.007 0.175 IssamiR-1308-3p 1.60 <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th>Q value</th>									Q value
hsa-miR-1998-5p 1.90 0.005 0.099 hsa-miR-32-5p 2.23 0.003 0.166 hsa-miR-22-3p 1.89 <0.001 0.028 hsa-miR-32-5p 2.21 0.006 0.175 hsa-miR-245p 1.75 0.012 0.133 hsa-miR-25p 2.17 0.030 0.265 hsa-miR-1995-5p 1.74 <0.001 0.020 hsa-miR-1916-5p 2.17 0.030 0.265 hsa-miR-337.5p 1.67 0.028 0.259 hsa-miR-1916-5p 2.11 0.023 0.257 hsa-miR-1938-3p 1.60 0.051 0.099 hsa-miR-1939-3p 2.10 0.001 0.121 hsa-miR-1938-3p 1.60 0.032 0.259 hsa-miR-1948-5p 2.00 0.002 0.121 hsa-miR-1938-3p 1.60 0.032 0.259 hsa-miR-1948-3p 2.00 0.002 0.121 hsa-miR-21-3p 1.51 0.006 0.099 hsa-miR-1488-3p 2.00 0.009 0.175 hsa-miR-21-3p 1.50 0.005 0.099 hsa-miR-148-3p 2.00 0.009 0.175 hsa-miR-21-3p 1.50 0.005 0.099 hsa-miR-142-5p 1.94 0.038 0.265 hsa-miR-21-3p 1.50 0.005 0.099 hsa-miR-142-5p 1.94 0.038 0.265 hsa-miR-21-3p 1.50 0.045 0.281 hsa-miR-142-5p 1.75 0.014 0.215 hsa-miR-21-3p 1.69 0.042 0.281 hsa-miR-21-3p 1.69 0.022 0.257 hsa-miR-21-3p 1.69 0.042 0.281 hsa-miR-21-3p 1.69 0.022 0.257 hsa-miR-21-3p 1.69 0.042 0.281 hsa-miR-21-3p 1.69 0.022 0.257 hsa-miR-21-3p 1.69 0.042 0.281 hsa-miR-21-3p 1.69 0.022 0.257 hsa-miR-244 1.59 0.044 0.281 hsa-miR-21-3p 1.69 0.022 0.257 hsa-miR-245p 1.61 0.010 0.121 hsa-miR-21-3p 1.69 0.022 0.257 hsa-miR-245p 1.61 0.013 0.259 hsa-miR-21-3p 1.62 0.008 0.175 hsa-miR-342-3p 1.60 0.002 0.051 hsa-miR-21-3p 1.62 0.008 0.175 hsa-miR-342-3p 1.90 0.002 0.051 hsa-miR-22-3p 1.62 0.008 0.175 hsa-miR-342-3p 1.90 0.002 0.051 hsa-miR-23-5p 1.61 0.013 0.226 hsa-miR-342-3p 1.90 0.002 0.051 hsa-miR-24-5p 1.53 0.027 0.263 hsa-miR-342-3p 1.50 0.033 0.259 hsa-miR-24-5p 1.52 0.040 0.266 hsa-miR-342-3p 1.60 0.033 0.265 hsa-miR-342-3p 1.61 0.013 0.226 hsa-miR-342-3p 1.61 0.013 0.265 hsa-miR-342-3p 1.62 0.040 0.266 hsa-miR-342-3p 1.62 0.040 0.266 hsa-miR-342-3p 1.61 0.013 0.265 hsa-miR-342-3p 1.61 0.013 0.265 hsa-miR-342-3p 1.64 0.033 0.265 hsa-miR-342-3p 1.64 0.033 0.265 hsa-miR-342-3p 1.68 0.012 0.205 hsa-miR-342-3p 1.68	hsa-miR-509-3p					hsa-miR-625-3p		0.016	0.224
hsa-miR-22-3p 1.89 <0.001	hsa-miR-199a-5p							0.003	0.156
hsa-miR-224-5p 1.75 0.009 0.121 hsa-miR-225p 2.18 0.020 0.242 hsa-miR-143-3p 1.75 0.012 0.133 hsa-miR-181b-5p 2.17 0.030 0.265 hsa-miR-1393-5p 1.67 0.028 0.259 hsa-miR-199a-5p 2.11 0.020 0.257 hsa-miR-199a-3p 1.61 0.001 0.050 hsa-miR-148a-5p 2.10 0.001 0.121 hsa-miR-139a-3p 1.60 0.032 0.259 hsa-miR-148a-3p 2.00 0.002 0.121 hsa-miR-139a-3p 1.60 0.032 0.259 hsa-miR-148a-3p 2.00 0.000 0.175 hsa-miR-123a-3p 1.50 0.005 0.099 hsa-miR-142-5p 1.94 0.038 0.285 hsa-miR-1424 -1.59 0.044 0.281 hsa-miR-142-5p 1.76 0.014 0.215 hsa-miR-1484 -1.72 0.010 0.028 hsa-miR-143-5p 1.69 0.022 0.257 hsa-miR-1484 -1.72 0.010 0.028 hsa-miR-193-5p 1.61 0.011 0.121	hsa-miR-22-3p								
hsamiR-143-3p 1.75 0.012 0.133 hsa-miR-181b-5p 2.17 0.030 0.265 hsa-miR-199b-5p 1.74 0.001 0.020 hsa-miR-199a-5p 2.12 0.008 0.175 hsa-miR-193b-3p 1.65 0.005 0.099 hsa-miR-199a-3p 2.10 0.001 0.121 hsa-miR-193a-3p 1.60 0.032 0.259 hsa-miR-193a-3p 2.00 0.002 0.121 hsa-miR-193a-3p 1.60 0.032 0.259 hsa-miR-193a-3p 2.00 0.009 0.175 hsa-miR-193a-3p 1.50 0.005 0.099 hsa-miR-148a-3p 2.00 0.007 0.175 hsa-miR-19a-3p 1.50 0.005 0.099 hsa-miR-142-5p 1.94 0.038 0.265 hsa-miR-1424 -1.59 0.044 0.281 hsa-miR-142-5p 1.94 0.032 0.257 hsa-miR-1446 -1.72 <0.01	hsa-miR-224-5p								
hsa-miR-1996-5p 1.74 <0.001	hsa-miR-143-3p								
hsa-miR-337-5p 1.67 0.028 0.259 hsa-miR-146a-5p 2.11 0.023 0.257 hsa-miR-199a-3p 1.61 0.001 0.050 hsa-miR-198a-3p 2.10 0.001 0.121 hsa-miR-199a-3p 1.61 0.002 0.259 hsa-miR-148a-3p 2.00 0.002 0.121 hsa-miR-130a-3p 1.51 0.006 0.099 hsa-miR-14a-3p 2.00 0.007 0.175 hsa-miR-21-3p 1.50 0.005 0.099 hsa-miR-142-5p 1.94 0.038 0.265 hsa-miR-1248 1.59 0.044 0.281 hsa-miR-142-5p 1.69 0.022 0.257 hsa-miR-1484 1.72 0.001 0.028 hsa-miR-21-3p 1.69 0.022 0.257 hsa-miR-1484 1.72 0.001 0.028 hsa-miR-21-3p 1.62 0.000 0.175 hsa-miR-759 1.83 0.009 0.121 hsa-miR-22-3p 1.62 0.000 0.175 hsa-miR-766-3p 1.93 0.033 0.259 hsa-miR-374a-5p 1.58 0.038 0.222	hsa-miR-199b-5p	1.74	< 0.001	0.020					
nsa-miR-338-3p 1.65 0.005 0.099 hsa-miR-199a-3p 2.10 0.001 0.121 hsa-miR-199a-3p 1.61 0.001 0.050 hsa-miR-148a-3p 2.00 0.002 0.121 hsa-miR-193a-3p 1.51 0.006 0.099 hsa-miR-148a-3p 2.00 0.007 0.175 hsa-miR-123-p 1.50 0.005 0.099 hsa-miR-142-5p 1.94 0.038 0.225 hsa-miR-1248 -1.59 0.044 0.281 hsa-miR-142-5p 1.94 0.038 0.225 hsa-miR-1484 -1.72 <0.001	hsa-miR-337-5p								
hsa-miR-199a-3p 1.61 0.001 0.050 hsa-miR-198a-3p 2.10 0.001 0.121 hsa-miR-193a-3p 1.60 0.032 0.259 hsa-miR-148a-3p 2.00 0.002 0.121 hsa-miR-193a-3p 1.51 0.006 0.099 hsa-miR-148a-3p 2.00 0.007 0.175 hsa-miR-21-3p 1.50 0.005 0.099 hsa-miR-142-5p 1.94 0.038 0.265 hsa-miR-1424 1.59 0.044 0.281 hsa-miR-142-5p 1.69 0.022 0.257 hsa-miR-1484 1.72 <0.001	hsa-miR-338-3p	1.65	0.005	0.099					
Ista-IIII-130a3p 1.00 0.002 0.239 hsa-miR-21-sp 2.00 0.009 0.175 hsa-miR-21-3p 1.50 0.005 0.099 hsa-miR-19a-3p 2.00 0.007 0.175 hsa-miR-21-3p 1.50 0.005 0.099 hsa-miR-19a-3p 2.00 0.007 0.175 hsa-miR-21-3p 1.53 0.044 0.281 hsa-miR-142-5p 1.94 0.038 0.265 hsa-miR-148b-5p 1.69 0.042 0.281 hsa-miR-17-5p 1.69 0.022 0.257 hsa-miR-75p 1.83 0.009 0.121 hsa-miR-22-3p 1.60 0.015 0.222 hsa-miR-766-3p 1.93 0.033 0.259 hsa-miR-370e-5p 1.61 0.015 0.222 hsa-miR-766-3p 1.93 0.033 0.259 hsa-miR-20b-5p 1.61 0.015 0.222 hsa-miR-766-3p 1.93 0.033 0.259 hsa-miR-20b-5p 1.53 0.027 0.263 hsa-miR-204-5p -2.11 0.	hsa-miR-199a-3p								
Bar-miR-213-p 1.50 0.005 0.099 hsa-miR-19a-3p 2.00 0.007 0.175 hsa-miR-27b-5p 1.53 0.045 0.281 hsa-miR-142-5p 1.94 0.038 0.265 hsa-miR-1428 -1.59 0.044 0.281 hsa-miR-142-5p 1.69 0.022 0.257 hsa-miR-1484 -1.72 <0.001	hsa-miR-193a-3p	1.60	0.032	0.259		hsa-miR-148a-3p	2.00	0.002	0.121
msa-miR-27b-5p -1.53 0.045 0.281 hsa-miR-1424-5p 1.94 0.038 0.265 hsa-miR-1248 -1.59 0.044 0.281 hsa-miR-21-3p 1.69 0.042 0.257 hsa-miR-1484 -1.72 <0.001	hsa-miR-130a-3p	1.51	0.006	0.099		hsa-miR-21-5p	2.00	0.009	0.175
hsa-miR-1248 -1.59 0.044 0.281 hsa-let-7i-5p 1.75 0.014 0.215 hsa-miR-1480-5p -1.69 0.042 0.281 hsa-miR-21-3p 1.69 0.022 0.257 hsa-miR-75p -1.83 0.009 0.121 hsa-miR-21-3p 1.67 0.001 0.121 hsa-miR-75p -1.83 0.009 0.121 hsa-miR-22-3p 1.62 0.008 0.175 hsa-miR-765.3p -1.93 0.032 0.259 hsa-miR-304-5p 1.61 0.015 0.222 hsa-miR-766.3p -1.93 0.033 0.259 hsa-miR-205-5p 1.61 0.016 0.226 hsa-miR-766.3p -1.93 0.033 0.259 hsa-miR-205-5p 1.53 0.027 0.263 hsa-miR-766.3p -2.11 0.011 0.132 hsa-miR-205-5p 1.55 0.018 0.228 hsa-miR-204-5p -2.12 0.044 0.281 hsa-miR-302-5p 1.60 0.033 0.266 hsa-miR-328-3p -2.12 0.010 0.334 hsa-miR-302-5p 1.60 0.033 0.266 <	hsa-miR-221-3p	1.50	0.005	0.099		hsa-miR-19a-3p	2.00	0.007	0.175
hsa-miR-146b-5p -1.69 0.042 0.281 hsa-miR-21-3p 1.69 0.022 0.257 hsa-miR-484 -1.72 <0.001	hsa-miR-27b-5p	-1.53	0.045	0.281		hsa-miR-142-5p	1.94	0.038	0.265
hsa-miR-44b-5p -1.69 0.042 0.281 hsa-miR-21-3p 1.69 0.022 0.257 hsa-miR-484 -1.72 <0.001	hsa-miR-1248	-1.59	0.044	0.281		hsa-let-7i-5p	1.75	0.014	0.215
hsa-miR-484 -1.72 <0.001	hsa-miR-146b-5p	-1.69	0.042	0.281					
hsa-miR-7-5p -1.83 0.009 0.121 hsa-miR-22-3p 1.62 0.008 0.175 hsa-miR-30-3p -1.84 0.035 0.259 hsa-miR-30e-5p 1.61 0.015 0.222 hsa-miR-766-3p -1.93 0.033 0.259 hsa-miR-30e-5p 1.58 0.038 0.265 hsa-miR-766-3p -1.93 0.033 0.259 hsa-miR-200-5p 1.53 0.027 0.263 hsa-miR-766-3p -2.12 0.010 0.132 hsa-miR-200-5p -1.52 0.040 0.266 hsa-miR-204-5p -2.12 0.044 0.281 hsa-miR-370-3p -1.60 0.033 0.265 hsa-miR-33-3p -2.21 0.010 0.34 hsa-miR-370-3p -1.64 0.033 0.265 hsa-miR-13-5p -2.57 0.031 0.259 hsa-miR-410-3p -1.68 0.012 0.205 hsa-miR-483-3p -5.76 <0.001	hsa-miR-484	-1.72	< 0.001	0.028					
hsa-miR-89-3p -1.84 0.035 0.259 hsa-miR-30e-5p 1.61 0.015 0.222 hsa-miR-766-3p -1.90 0.002 0.061 hsa-miR-374a-5p 1.58 0.038 0.265 hsa-miR-766-3p -1.93 0.033 0.259 hsa-miR-200b-3p 1.53 0.027 0.263 hsa-miR-204-5p -2.11 0.011 0.132 hsa-miR-20b-5p -1.52 0.040 0.266 hsa-miR-204-5p -2.12 0.014 0.281 hsa-miR-320-3p -1.60 0.033 0.265 hsa-miR-328-3p -2.19 <0.001	hsa-miR-7-5p	-1.83	0.009	0.121					
hsa-miR-342-3p -1.90 0.002 0.051 hsa-miR-374a-5p 1.58 0.038 0.265 hsa-miR-421 -2.02 0.010 0.132 hsa-miR-20b-3p 1.53 0.027 0.263 hsa-miR-421 -2.02 0.010 0.132 hsa-miR-20b-3p 1.53 0.027 0.263 hsa-miR-421 -2.02 0.010 0.132 hsa-miR-20b-5p 1.55 0.040 0.266 hsa-miR-204-5p -2.12 0.044 0.281 hsa-miR-342-3p 1.60 0.033 0.228 hsa-miR-32a-3p -2.21 0.012 0.133 hsa-miR-342-3p 1.64 0.033 0.266 hsa-miR-31-5p -2.27 0.031 0.259 hsa-miR-410-3p 1.68 0.039 0.266 hsa-miR-483-3p -2.78 0.030 0.090 hsa-miR-126b-2-3p 1.68 0.012 0.205 hsa-miR-483-3p -5.76 <0.001	hsa-miR-93-3p	-1.84	0.035	0.259					
nisa-miR-400-3p -1.93 0.033 0.259 hsa-miR-200b-3p 1.53 0.027 0.263 hsa-miR-10a-5p -2.11 0.010 0.132 hsa-miR-27b-5p 1.52 0.040 0.266 hsa-miR-204-5p -2.12 0.044 0.281 hsa-miR-30-5p -1.55 0.018 0.228 hsa-miR-23-5p -2.19 <0.001	hsa-miR-342-3p								
isad-miR-421 2.002 0.010 0.132 hsa-miR-27b-5p -1.52 0.040 0.266 isad-miR-204-5p -2.11 0.011 0.133 hsa-miR-100-5p -1.55 0.018 0.228 isad-miR-204-5p -2.12 0.012 0.133 hsa-miR-342-3p -1.60 0.033 0.265 isad-miR-31-5p -2.21 0.012 0.133 hsa-miR-370-3p -1.64 0.033 0.265 isad-miR-633 -2.78 0.003 0.090 hsa-miR-410-3p -1.68 0.012 0.205 isad-miR-633 -2.76 0.001 0.028 hsa-miR-125b-2-3p -1.68 0.012 0.205 isad-miR-633 -5.76 <0.001	hsa-miR-766-3p	-1.93	0.033	0.259					
Nature No.044 0.281 hsa-miR-100-5p -1.55 0.018 0.228 hsa-miR-242-3p -2.21 0.044 0.281 hsa-miR-342-3p -1.60 0.033 0.265 hsa-miR-33-2p -2.21 0.012 0.133 hsa-miR-342-3p -1.64 0.033 0.266 hsa-miR-433-3p -2.27 0.031 0.259 hsa-miR-410-3p -1.68 0.039 0.266 hsa-miR-483-3p -2.78 0.003 0.090 hsa-miR-125b-2-3p -1.68 0.012 0.205 hsa-miR-483-3p -5.76 <0.001	hsa-miR-421								
hsa-miR-328-3p -2.19 <0.001	hsa-miR-10a-5p								
hsa-miR-433-3p -2.21 0.012 0.133 hsa-miR-370-3p -1.64 0.033 0.265 hsa-miR-31-5p -2.57 0.031 0.259 hsa-miR-410-3p -1.68 0.039 0.266 hsa-miR-483-3p -2.78 0.003 0.090 hsa-miR-125b-2-3p -1.68 0.012 0.205 hsa-miR-483-3p -5.76 <0.001	hsa-miR-204-5p								
hsa-miR-31-5p -2.57 0.031 0.259 hsa-miR-410-3p -1.68 0.039 0.266 hsa-miR-663a -2.78 0.003 0.090 hsa-miR-125b-2-3p 1.68 0.012 0.205 hsa-miR-83-3p -5.76 <0.001	hsa-miR-328-3p								
hsa-miR-663a -2.78 0.003 0.090 hsa-miR-125b-2-3p -1.68 0.012 0.205 hsa-miR-483-3p -5.76 <0.001									
hsa-miR-483-3p -5.76 <0.001 0.028 1.84-miR-12/02-5p -1.05 0.012 0.203 tmaps of significantly differential expressed microRNAs paring erythrodermic mycosis fungoides (eMF) vs. early-throdermic (SS) vs. early-stage MF. Heatmap and Sézary syndrome (SS) vs. early-stage MF. Heatmap and 1.84-miR-12/02-5p -1.05 0.012 0.203 0.203 hsa-miR-12/02-5p -1.77 0.032 0.265 1.77 0.032 0.265 hsa-miR-12/02-5p -1.79 0.043 0.276 hsa-miR-328-3p -1.96 0.004 0.121 hsa-miR-328-3p -1.96 0.008 0.174						hsa-miR-410-3p	-1.68	0.039	0.266
tmaps of significantly differential expressed microRNAs hsa-miR-303-5p -1.77 0.032 0.265 baring erythrodermic mycosis fungoides (eMF) vs. early- hsa-miR-391-5p -1.79 0.043 0.276 hsa-miR-328-3p -1.84 0.001 0.121 hsa-miR-326 -1.96 0.004 0.174						hsa-miR-125b-2-3p	-1.68	0.012	0.205
hsa-miR-491-5p -1.79 0.043 0.276 hsa-miR-484 -1.84 0.001 0.121 hsa-miR-328-3p -1.96 0.004 0.174 hsa-miR-328-3p -1.96 0.004 0.174 hsa-miR-328-3p -1.98 0.008 0.175	hsa-miR-483-3p	-5.76	<0.001	0.028		hsa-miR-503-5p	-1.77	0.032	0.265
hsa-miR-484 -1.84 0.001 0.121 hsa-miR-328-3p -1.96 0.004 0.174 hsa-miR-328-3p -1.98 0.008 0.175	tmane of sign	ificantly differen	tial over	accod mi	croPNAc				
Sparing erythrodermic mycosis fungoides (eMF) vs. early- hsa-miR-328-3p -1.96 0.004 0.174 ad Sézary syndrome (SS) vs. early-stage MF. Heatmap and hsa-miR-326 -1.98 0.008 0.175									
nd Sézary syndrome (SS) vs. early-stage MF. Heatmap and hsa-miR-326 1.98 0.008 0.175	aring erythro	odermic mycosis	tungoide	es (eMF) v	s. early-				
	nd Sézary svn	drome (SS) vs. ea	arly-stad	e MF. Hea	tmap and				
		• •	, .			hsa-miR-433-3p	-2.03	0.008	0.228

hsa-miR-663a

hsa-miR-193b-5p

hsa-miR-483-3p

when comparing erythrodermic mycosis fungoides (eMF) vs. earlystage MF and Sézary syndrome (SS) vs. early-stage MF. Heatmap and unsupervised 2-way hierarchical clustering based on significantly regulated microRNAs. (A) Shows the 29 microRNAs that differ the most between eMF and early-stage disease. (B) Represents the 36 microRNAs that differ the most between SS and early-stage disease.

pathways associated with cancer (i.e. mitogen-activated protein kinase (MAPK), tumour necrosis factor (TNF), T-cell receptors, mechanistic target of rapamycin kinase (mTOR), and phosphatidylinositol 3-kinase-serine/threo-nine kinase (PI3K-Akt).

DISCUSSION

This study provides evidence that the miRNA expression profile in lesional skin can discriminate eMF from SS. Twenty-seven miRNAs separated the 2 disease entities and were significantly differentially expressed between eMF and SS. Moreover, the miRNA expression profile of eMF differs from both SS and early-stage MF; however, hierarchical clustering showed that eMF co-clustered with early-stage rather than SS.

It is essential to discriminate eMF from SS due to differences in treatment recommendation and prognosis, with patients with SS in stage B2 having significantly higher mortality rates (4, 30). Several studies have indicated that miRNAs are involved in the pathogenesis and disease

progression and serve as markers of diagnosis and prognosis in CTCL (18-21, 23, 29, 31). In this study, 19 out of the 27 significantly differentially expressed miRNAs between eMF and SS have previously been linked to CTCL (15, 16, 18, 21, 28, 32). In particular, miR-106b, miR-155 and miR-21 showed significantly higher expression levels in SS and have previously been associated with progression of CTCL: miR-106b was included in the prognostic miRNA classifier developed for early-stage CTCL (21) and miR-21 is induced by IL15 and STAT5, which are important regulators of proliferation and cell survival in CTCL (29, 33). Most widely investigated is the STAT5 regulated miR-155 (22). There is a higher expression of miR-155 in SS compared with MF (34). Expression levels of miR-155 increases with MF stage (35) and a recent identified diagnostic- and prognostic classier includes miR-155 expression levels (36). Due to its role in constitutive activation of important intracellular signalling pathways, and proliferation of malignant T cells, miR-155 is a promising therapeutic target in CTCL (22, 37). Another potential miRNA target in CTCL is miR-214

0.025

0.007

0.009

0.259

0.175

0.175

-2.65

-3.17

-4.71

Fig. 2.




Fig. 3. Heatmap of significantly differential expressed microRNAs between Sézary syndrome (SS), erythrodermic mycosis fungoides (eMF), and early-stage MF. Heatmap and unsupervised 2-way hierarchical clustering showing the 54 distinctive (p < 0.05) microRNAs between SS, eMF, and early-stage disease.

(38, 39). In addition, we found higher expression levels of miR-181a and miR-146a in the advanced stages of CTCL. Manso et al. showed a similar expression pattern and hypothesized miR-181a and miR-146a to play a role in disease progression (40).

Table II. Extrapolation of the significantly differently expressed microRNAs in the comparison of Sézary syndrome and erythrodermic mycosis fungoides skin using the mirPath v.3 database to enlighten the association to different genes in selected Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways

KEGG pathway	<i>p</i> -value	Regulated genes n	miRNAs involved in KEGG pathways n
Pathways in cancer	1×10-6	220	27
MAPK signalling pathway	8×10-5	144	27
TNF signalling pathway	< 0.001	65	27
T-cell receptor signalling pathways	0.002	63	25
mTOR signalling pathway	0.002	39	25
PI3K-Akt signalling pathway	0.006	171	27

MAPK; mitogen-activated protein kinase; TNF; tumour necrosis factor; mTOR; mechanistic target of rapamycin kinase; PI3K-Akt; phosphatidylinositol 3-kinase-serine/threonine kinase.

Accordingly, the identified miRNA signature may play an important role in the pathogenesis and progression of CTCL. Moreover, the downstream signalling of the discriminative miRNAs between eMF and SS revealed signalling pathways fundamental in CTCL, which is indicative of the importance of these miRNAs (Table II).

Taken together, the present findings strongly indicate that miRNAs are important players in the CTCL pathogenesis and that the miRNA expression profile reflects the stage, aggressiveness, and disease entity of CTCL.

The study is limited by its retrospective design, and a prospective validation of the findings would have been preferred. Moreover, despite the rarity of CTCL, we would have preferred to include a larger number of patients.

The Danish registry system enabled identification of the specific biopsy used for the first diagnosis of eMF, SS, and early-stage MF and precise linkage to clinical characteristics of each individual patient, which strengthens the study. The technical and biological robustness of miRNAs in FFPE-preserved skin biopsies is a further strength of the study.

In conclusion, the miRNA expression profile in diagnostic skin biopsies can discriminate eMF from SS despite clinical and histological similarities. These results emphasize that eMF and SS represent distinct disease entities based on the miRNA signature of skin.

ACKNOWLEDGEMENTS

This study was supported by grants from LINAK A/S Nordborg, The Novo Nordisk Research Foundation – The Tandem Program NNF14OC0012345; the Danish Cancer Society (Kræftens Bekæmpelse), the Fight Cancer Program (Knæk Cancer) and Aage Bangs Foundation.

Conflicts of interest. TL is employed at both University of Copenhagen and LEO Pharma A/S. NO is unpaid member of the Scientific Advisory Board, MiNDERA Corp., CA 94080, USA, with no financial interests or associations. LI served as a consultant and/ or paid speaker for and/or participated in clinical trials sponsored by: AbbVie, Almirall, Amgen, Astra Zeneca, BMS, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, Janssen Cilag, Kyowa, Leo Pharma, MSD, Novartis, Pfizer, Samsung, UCB. The other authors have nothing to declare.

REFERENCES

- 1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768–3785.
- Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113: 5064–5073.
- Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome – Update 2017. Eur J Cancer 2017; 77: 57–74.
- 4. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification

of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713–1722.

- Kohler S, Kim YH, Smoller BR. Histologic criteria for the diagnosis of erythrodermic mycosis fungoides and Sezary syndrome: a critical reappraisal. J Cutan Pathol 1997; 24: 292–297.
- Moriarty B, Whittaker S. Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma. Expert Rev Hematol 2015; 8: 159–171.
- Scarisbrick JJ, Hodak E, Bagot M, Stranzenbach R, Stadler R, Ortiz-Romero PL, et al. Blood classification and blood response criteria in mycosis fungoides and Sezary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Eur J Cancer 2018; 93: 47–56.
- Thiers BH. Controversies in mycosis fungoides. J Am Acad Dermatol 1982; 7: 1–16.
- 9. van Doorn R, van Kester MS, Dijkman R, Vermeer MH, Mulder AA, Szuhai K, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood 2009; 113: 127–136.
- Hurabielle C, Michel L, Ram-Wolff C, Battistella M, Jean-Louis F, Beylot-Barry M, et al. Expression of Sezary biomarkers in the blood of patients with erythrodermic mycosis fungoides. J Invest Dermatol 2016; 136: 317–320.
- Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. Arch Dermatol 1995; 131: 1003–1008.
- Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/ European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28: 4730–4739.
- Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843–854.
- 14. Esquela-Kerscher A, Slack FJ. Oncomirs microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259–269.
- Ballabio E, Mitchell T, van Kester MS, Taylor S, Dunlop HM, Chi J, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood 2010; 116: 1105–1113.
- van Kester MS, Ballabio E, Benner MF, Chen XH, Saunders NJ, van der Fits L, et al. miRNA expression profiling of mycosis fungoides. Mol Oncol 2011; 5: 273–280.
- Maj J, Jankowska-Konsur A, Sadakierska-Chudy A, Noga L, Reich A. Altered microRNA expression in mycosis fungoides. Br J Dermatol 2012; 166: 331–336.
- Ralfkiaer U, Lindahl LM, Litman T, Gjerdrum LM, Ahler CB, Gniadecki R, et al. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma. Anticancer Res 2014; 34: 7207–7217.
- Marstrand T, Ahler CB, Ralfkiaer U, Clemmensen A, Kopp KL, Sibbesen NA, et al. Validation of a diagnostic microRNA classifier in cutaneous T-cell lymphomas. Leuk Lymphoma 2014; 55: 957–958.
- Ralfkiaer U, Hagedorn PH, Bangsgaard N, Lovendorf MB, Ahler CB, Svensson L, et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 2011; 118: 5891–5900.
- Lindahl LM, Besenbacher S, Rittig AH, Celis P, Willerslev-Olsen A, Gjerdrum LMR, et al. Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study. Blood 2018; 131: 759–770.
- 22. Kopp KL, Ralfkiaer U, Gjerdrum LM, Helvad R, Pedersen IH, Litman T, et al. STAT5-mediated expression of oncogenic

miR-155 in cutaneous T-cell lymphoma. Cell Cycle 2013; 12: 1939–1947.

- Tensen CP, Vermeer MH. MicroRNA-155 potentiates tumour development in mycosis fungoides. Br J Dermatol 2017; 177: 618–620.
- 24. Seto AG, Beatty X, Lynch JM, Hermreck M, Tetzlaff M, Duvic M, et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br J Haematol 2018; 183: 428–444.
- Bunn PA, Jr., Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 1979; 63: 725–728.
- Russell-Jones R, Whittaker S. T-cell receptor gene analysis in the diagnosis of Sezary syndrome. J Am Acad Dermatol 1999; 41: 254–259.
- Vlachos IS, Zagganas K, Paraskevopoulou MD, Georgakilas G, Karagkouni D, Vergoulis T, et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res 2015; 43: W460–466.
- Sandoval J, Diaz-Lagares A, Salgado R, Servitje O, Climent F, Ortiz-Romero PL, et al. MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma. J Invest Dermatol 2015; 135: 1128–1137.
- 29. Lindahl LM, Fredholm S, Joseph C, Nielsen BS, Jonson L, Willerslev-Olsen A, et al. STAT5 induces miR-21 expression in cutaneous T cell lymphoma. Oncotarget 2016; 7: 45730–45744.
- Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol 2015; 33: 3766–3773.
- Narducci MG, Arcelli D, Picchio MC, Lazzeri C, Pagani E, Sampogna F, et al. MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sezary syndrome. Cell Death Dis 2011; 2: e151.
- 32. Gallardo F, Sandoval J, Diaz-Lagares A, Garcia R, D'Altri T, Gonzalez J, et al. Notch1 pathway activation results from the epigenetic abrogation of notch-related microRNAs in mycosis fungoides. J Invest Dermatol 2015; 135: 3144–3152.
- Mishra A, La Perle K, Kwiatkowski S, Sullivan LA, Sams GH, Johns J, et al. Mechanism, consequences, and therapeutic targeting of abnormal IL15 signaling in cutaneous T-cell lymphoma. Cancer Discov 2016; 6: 986–1005.
- Fava P, Bergallo M, Astrua C, Brizio M, Galliano I, Montanari P, et al. miR-155 expression in primary cutaneous t-cell lymphomas (CTCL). J Eur Acad Dermatol Venereol 2017; 31: e27-e29.
- Moyal L, Barzilai A, Gorovitz B, Hirshberg A, Amariglio N, Jacob-Hirsch J, et al. miR-155 is involved in tumor progression of mycosis fungoides. Exp Dermatol 2013; 22: 431–433.
- Shen X, Wang B, Li K, Wang L, Zhao X, Xue F, et al. MicroRNA signatures in diagnosis and prognosis of cutaneous T-cell lymphoma. J Invest Dermatol 2018; 138: 2024–2032.
- Ma X, Becker Buscaglia LE, Barker JR, Li Y. MicroRNAs in NFkappaB signaling. J Mol Cell Biol 2011; 3: 159–166.
- Kohnken R, McNeil B, Wen J, McConnell K, Grinshpun L, Keiter A, et al. Preclinical targeting of microRNA-214 in cutaneous T-cell lymphoma. J Invest Dermatol 2019 Mar 12. [Epub ahead of print].
- 39. Kohnken R, Mishra A. microRNAs in cutaneous T-cell lymphoma: the future of therapy. J Invest Dermatol 2019; 139: 528–534.
- Manso R, Martinez-Magunacelaya N, Erana-Tomas I, Monsalvez V, Rodriguez-Peralto JL, Ortiz-Romero PL, et al. Mycosis fungoides progression could be regulated by microRNAs. PLoS One 2018; 13: e0198477.